KEAP1 and Hyperglycemia: In our study, the NaHS treatment in primary cardiomyocyte cultures subjected to hyperglycemia, HR, or both conditions promoted an increase in the expression of Nrf2 (Figure 9C) and a decrease in the expression of its regulator Keap1 (Figure 9B).